cilofexor (GS-9674) / Gilead  >>  Phase 2
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cilofexor (GS-9674) / Gilead
NCT01999101 / 2013-002984-24: Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients

Completed
2
12
Europe
Px-104
Phenex Pharmaceuticals AG, Medical University of Vienna
Non Alcoholic Fatty Liver Disease
01/15
06/16
NCT02854605 / 2016-002496-10: Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Checkmark ATLAS
Nov 2018 - Nov 2018: ATLAS
Completed
2
140
Canada, US, Europe, RoW
GS-9674, Placebo to match GS-9674
Gilead Sciences
Nonalcoholic Steatohepatitis (NASH)
01/18
01/18
NCT02943460 / 2016-002442-23: Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Completed
2
52
Europe, Canada, US
Cilofexor, GS-9674, Placebo to match cilofexor
Gilead Sciences
Primary Sclerosing Cholangitis
02/18
05/20
NCT02943447 / 2016-002443-42: Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

Terminated
2
71
Europe, Canada, US
Cilofexor, GS-9674, Placebo to match cilofexor
Gilead Sciences
Primary Biliary Cholangitis
09/19
09/19
ATLAS, NCT03449446: Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Checkmark Efficacy data from ATLAS trial in combination with cilofexor and firsocostat in patients with advanced fibrosis (F3-F4) due to NASH
Dec 2019 - Dec 2019: Efficacy data from ATLAS trial in combination with cilofexor and firsocostat in patients with advanced fibrosis (F3-F4) due to NASH
Checkmark 48-week data from ATLAS trial in combination with GS-0976 and GS-9674 for non-alcoholic steatohepatitis
Dec 2019 - Dec 2019: 48-week data from ATLAS trial in combination with GS-0976 and GS-9674 for non-alcoholic steatohepatitis
Checkmark ATLAS
More
Completed
2
395
Canada, US, RoW
SEL, FIR, GS-0976, CILO, GS-9674, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL
Gilead Sciences
Nonalcoholic Steatohepatitis
10/19
11/19
NCT03987074: Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

Completed
2
109
US
Semaglutide, Firsocostat, GS-0976, Cilofexor, GS-9674
Gilead Sciences, Novo Nordisk A/S
Nonalcoholic Steatohepatitis
07/20
07/20
NCT02781584: Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

Completed
2
220
US, RoW
SEL, GS-4997, FIR, GS-0976, CILO, GS-9674, FENO, VAS
Gilead Sciences
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
12/20
12/20
2021-001445-12: A study to assess the safety and efficacy of Semaglutide and the fixed dose combination of Cilofexor and Firsocostat, alone and in combination, in subjects with Chirrhosis due to Nonalcoholic Steatohepatitis (NASH) Un estudio para para evaluar la seguridad y la eficacia de Semaglutida y la dosis fija de Cilofexor y Firsocostat, en monoterapia y en combinación, en pacientes con Cirrosis debida a Esteatohepatitis No Alcohólica (EHNA)

Not yet recruiting
2
440
Europe
Semaglutide B 3.0 mg/ml PDS290, Cilofexor/Firsocostat (CILO/FIR) tablets, 30/20mg, GS-9674/GS-0976, Solution for injection, Film-coated tablet
Gilead Sciences, Inc., Gilead Sciences, Inc
Nonalcoholic Steatohepatitis (NASH) Esteatohepatitis No Alcohólica (EHNA), Inflammation of the liver Inflamación del hígado, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT04971785: Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Active, not recruiting
2
457
Europe, Canada, Japan, US, RoW
Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), GS-9674/GS-0976, PTM SEMA, PTM CILO/FIR
Gilead Sciences, Novo Nordisk A/S
Nonalcoholic Steatohepatitis
11/24
12/24

Download Options